Opdivo-Avastin Combo Safe, Has Strong Activity in Relapsed Ovarian Cancer Patients, Phase 2 Trial Shows

Opdivo-Avastin Combo Safe, Has Strong Activity in Relapsed Ovarian Cancer Patients, Phase 2 Trial Shows
A combination of Opdivo (nivolumab) and Avastin (bevacizumab) is safe and has strong clinical activity in women with relapsed ovarian cancer, especially among those whose tumors were sensitive to platinum-based chemotherapy, a Phase 2 clinical trial shows. The study, "Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial," was published in JAMA Oncology. Immune checkpoint inhibitors are therapies based on the principle of removing the “brakes” of our immune system, to use the power of the body’s immune system to fight cancer faster and more effectively. Opdivo, by Bristol-Myers Squibb, is included in this group of therapies, and works by binding to a protein found on the surface of immune cells called programmed cell death (PD-1) and prevent it from interacting with its ligands, PD-L1 and PD-L2, which are produced by cancer cells. This disruption in the PD-1 signaling pathw
Subscribe or to access all post and page content.